Megan Stauffer, MD
Allergy & Immunology · Hermitage, TNNPI 1407977184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 380 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,726, 4.9 times the $353 reported in 2019.
Across 380 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- CSL Behring$1K
- Sanofi$980
- GSK$494
- Regeneron Healthcare Solutions, Inc.$433
- Genentech USA, Inc.$317
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,644100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $1,481 |
| CSL Behring | 72 | $1,338 |
| Sanofi | 42 | $980 |
| GSK | 33 | $494 |
| Regeneron Healthcare Solutions, Inc. | 15 | $433 |
| Genentech USA, Inc. | 15 | $317 |
| Octapharma USA, Inc. | 6 | $252 |
| Optinose US, Inc. | 13 | $249 |
| Novartis | 13 | $245 |
| Biocryst US Sales Co., LLC | 11 | $211 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $206 |
| Amgen | 10 | $186 |
| ARS Pharmaceuticals Operations, Inc. | 12 | $171 |
| Kaleo, Inc. | 10 | $163 |
| Pfizer | 6 | $124 |
| Cycle Pharmaceuticals Inc | 4 | $122 |
| Boehringer Ingelheim | 5 | $99 |
| Grifols USA, LLC | 4 | $84 |
| Teva Pharmaceuticals USA, Inc. | 5 | $75 |
| Genentech, Inc. | 2 | $67 |
| Alk-abello, Inc | 3 | $55 |
| Phadia US Inc. | 3 | $53 |
| Pharming Healthcare, Inc. | 2 | $44 |
| Ionis Pharmaceuticals, Inc. | 2 | $37 |
| Blueprint Medicines Corporation | 2 | $35 |
| Mylan Specialty L.p. | 2 | $30 |
| LEO Pharma Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $16 |
| USWM, LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,671 in reported general payments places this provider in the 55th percentile of 79 allergy & immunology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 65 | $217,856 |
| FasenraBenralizumab | 12 | $67,534 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 22 | $58,596 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $49,392 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $19,595 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,295 |
| Spiriva RespimatTiotropium Bromide | 16 | $12,129 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $7,842 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $5,792 |
| Epinephrine | 23 | $5,698 |
| Arnuity ElliptaFluticasone Furoate | 13 | $5,286 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $3,206 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,479 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,079 |
| Azelastine Hcl | 50 | $1,613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $67 | $217,85665 claims |
| AstraZenecaFasenra, Symbicort | $1,481 | $75,37630 claims |
| Grifols USA, LLCGamunex-C | $84 | $58,59622 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $206 | $49,39212 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $494 | $38,17680 claims |
| Boehringer IngelheimSpiriva Respimat | $99 | $12,12916 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $5,69823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 79 allergy & immunology providers in Tennessee.
Other allergy & immunology in Hermitage
- William CainHermitage$10K
- Nicholas KolinskyKnoxville$472K
- Tidence PrinceMaryville$269K
- Tammy Heinly McCulleyGermantown$165K
- Phillip LiebermanMemphis$131K
- John FahrenholzNashville$124K
- Marc CromieChattanooga$106K
- Reena PatelMemphis$101K
- Jay LiebermanMemphis$81K
- Katherine CahillNashville$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.